
### **Trend of Opdivo**

**November 1, 2019** 




#### Sales of Opdivo by Each Cancer (Estimation)




Dosage and administration re-pricing in Nov 2018 (-37.5%)

Source: Estimation from external and internal data


### Number of Patients Newly Prescribed with Opdivo by Each Cancer (Estimation)



#### Sales Ratio of ICPIs in All Types of Cancer (Estimation)




#### Sales Ratio of ICPIs in NSCLC (Estimation)




## Prescription Ratio in Patients Newly Treated for 3<sup>rd</sup> Line Gastric Cancer \*\* Patients starting 3<sup>rd</sup> line treatment of gastric cancer

※ Patients starting 3<sup>rd</sup> line treatment of gastric cancer within the last 3 months



Source: External data (Jul 2017 – Aug 2019: n=190~250)


# Annual Drug-treated Patients with Advanced or Metastatic RCC in Japan



Estimation based on internal survey (2018)


### Prescription Ratio in Patients Newly Treated for Advanced or Metastatic 1<sup>st</sup> Line RCC

	2018			2019				
	Jun	Sep	Dec	Mar	Jun	Oct		
Opdivo	-	7	29	32	47	49	(%)	
Product E	46	40	30	36	20	29	(%)	
Product F	41	41	32	26	28	21	(%)	



### Prescription Ratio in Patients Newly Treated for Advanced or Metastatic 2<sup>nd</sup> Line RCC

	2016 2017	017				2018			2019				
	Nov	Feb	May	Aug	Nov	Mar	Jun	Sep	Dec	Mar	Jun	Oct	_
Opdivo	8	15	32	38	42	47	36	49	<b>54</b>	48	63	<b>51</b>	(%)
Product D	69	59	55	48	40	31	51	27	27	44	29	38	(%)



Source: External data (Sep 2018 - Oct 2019: n=32~57)



Dedicated to Man's Fight against Disease and Pain